$RGNX just saw its ACCE composite score fall 14 points, from 52 to 38 out of 100. That is a meaningful single-move drop, and the current score breakdown tells a clear story about where the pressure is coming from.
The four subscore readings right now: Growth 64, Value 11, Quality 44, Momentum 34. Two of those four are in genuinely weak territory, and one is near the floor.
What the subscores say
Value (11/100) is the most striking number in the breakdown. A score that low typically reflects a combination of a negative forward P/E (currently -2.7, meaning the company is not yet profitable on a forward basis) and metrics like FCF yield sitting at -17.9%. When a stock is burning cash and has no near-term earnings to anchor a valuation, value-oriented scoring models will penalise it heavily. This subscore alone drags the composite down significantly.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Momentum (34/100) is the other weak point. $RGNX is down 8.5% over the past year, and momentum subscores tend to track price trends across multiple lookback windows. A stock that has underperformed over a 12-month horizon, with no strong near-term reversal, will score poorly here. A deteriorating momentum reading is one of the most common drivers of a sharp composite score drop, because it compounds whatever fundamental weakness already exists.
Quality (44/100) sits in the middle of the range but carries some red flags. ROE is -137.6%, net margin is -112.6%, and the earnings quality flag is listed as concerning. These figures reflect a pre-profitability biotech that is spending heavily relative to its revenue base. Quality subscores reward consistency, margin strength, and capital efficiency — none of which $RGNX can demonstrate right now.
Growth (64/100) is the one bright spot. Year-over-year revenue is up 405.7%, which is a substantial top-line expansion and likely the reason the growth subscore is holding up. The company also beat Q3 FY2026 earnings estimates by 2.6%. But year-over-year earnings growth is listed at 0.0%, so the revenue surge has not yet translated into bottom-line improvement.
What it means
A 14-point composite drop of this kind usually reflects a combination of momentum deterioration and a reassessment of quality or value metrics rather than a single event. With Value at 11 and Momentum at 34, $RGNX is carrying two structurally weak subscores that are hard to offset even with strong revenue growth.
The analyst consensus target sits at $24.55 against a current price of $8.24, which implies significant upside on paper. But the ACCE score of 38 reflects the risk profile embedded in reaching that target — negative margins, negative cash flow, and a stock that has lost ground over the past year.
For current pricing and score updates, see the live $RGNX page at acceinvestments.com/stocks/RGNX.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
